Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Optimizing bexarotene therapy for cutaneous T-cell lymphoma.

Rakhshandra Talpur1, Staci Ward, Narin Apisarnthanarax

  • 1Division of Internal Medicine, Department of Dermatology, The University of Texas M. D. Anderson Cancer Center, Houston, TX 77030, USA.

Journal of the American Academy of Dermatology
|October 26, 2002
PubMed
Summary

Bexarotene monotherapy showed a 48% response rate in cutaneous T-cell lymphoma (CTCL). Combining bexarotene with lipid-lowering agents, particularly two, significantly increased response rates to 90%.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Editor's Note: Essential Role of DNA Methyltransferase 1-mediated Transcription of Insulin-like Growth Factor 2 in Resistance to Histone Deacetylase Inhibitors.

Clinical cancer research : an official journal of the American Association for Cancer Research·2026
Same author

Tumor flare reaction with brentuximab-vedotin in mycosis fungoides.

JAAD case reports·2026
Same author

Long-term outcomes in juvenile-onset mycosis fungoides.

Journal of the American Academy of Dermatology·2026
Same author

Correction: BRAF inhibitors suppress apoptosis through off-target inhibition of JNK signaling.

eLife·2026
Same author

ISCL/EORTC-CLTG/USCLC recommendations for the diagnosis, staging and treatment of early-stage paediatric mycosis fungoides: a modified Delphi consensus. Part two: treatment.

The British journal of dermatology·2025
Same author

ISCL/EORTC-CLTG/USCLC recommendations for the diagnosis, staging and treatment of early-stage paediatric mycosis fungoides: a modified Delphi consensus. Part one: diagnosis and staging.

The British journal of dermatology·2025

Area of Science:

  • Oncology
  • Dermatology
  • Pharmacology

Background:

  • Bexarotene is an approved treatment for cutaneous T-cell lymphoma (CTCL), but hypertriglyceridemia is a common side effect.
  • Lipid-lowering agents (LLAs) are often used with bexarotene, and statins may influence T-cell responses.
  • Optimizing bexarotene treatment involves managing side effects and exploring combination therapies.

Observation:

  • This study prospectively evaluated 70 patients with CTCL treated with oral bexarotene.
  • Bexarotene was administered as monotherapy or in combination with other agents.
  • Lipid-lowering agents, including statins, were used to manage hypertriglyceridemia.

Findings:

  • Bexarotene monotherapy achieved an overall response rate (RR) of 48% in CTCL patients.

Related Experiment Videos

  • Patients receiving two LLAs with bexarotene showed a significantly higher RR (90%) compared to those on one or no LLAs.
  • Combination therapy with bexarotene and other CTCL treatments resulted in higher RRs (69%) in advanced disease patients without significant toxicity.

    • Implications:

    • Bexarotene is a safe and effective monotherapy and combination therapy for CTCL.
    • Combination therapy, especially with multiple LLAs, may improve bexarotene efficacy and allow for higher doses.
    • Further research into bexarotene's immunomodulatory effects and combination strategies is warranted for advanced CTCL.